BioRestorative Therapies, Inc. (BRTX) shareholders
Close on Nov 17, 2026Market cap $34.14MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Louis Posner Joint filing with Auctus Fund, LLC (9.90%), Auctus Fund Management LLC (9.90%) and 1 more | 2,699,470 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Alstodt Lance | 1,236,809 | 15.50% | 13D (active) amendment | Feb 14, 2025 |
| Silva, Francisco | 1,196,819 | 15.10% | 13D (active) amendment | Feb 14, 2025 |
| Dale Broadrick | 926,376 | – | 13D (active) amendment | Feb 8, 2024 |
| Alfred Sollami Joint filing with Auctus Fund Management LLC (9.90%), Auctus Fund, LLC (9.90%) and 1 more | 692,418 | 9.90% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BRTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 40,176 | 0.16% | $302.12K | New | 0.00% |
| Hrt Financial LP | 35,530 | 0.14% | $267.00K | New | 0.00% |
| XTX Topco Ltd | 14,325 | 0.06% | $107.73K | New | 0.00% |
| Citadel Advisors LLC | 13,665 | 0.05% | $102.76K | +1,735 | 0.00% |
| Vanguard Fiduciary Trust Co | 9,065 | 0.04% | $68.17K | +7,092 | 0.00% |
| Geode Capital Management, LLC | 7,621 | 0.03% | $57.31K | −3,534 | 0.00% |
| Citigroup Inc | 3,186 | 0.01% | $23.96K | New | 0.00% |
| Wealth Alliance | 2,000 | 0.01% | $15.04K | – | 0.00% |
| State Street Corp | 1,623 | 0.01% | $12.21K | – | 0.00% |
| Keystone Financial Group | 1,430 | 0.01% | $10.75K | New | 0.00% |
| Northern Trust Corp | 1,200 | 0.00% | $9.03K | New | 0.00% |
| Creative Planning | 1,087 | 0.00% | $8.17K | New | 0.00% |
| Susquehanna International Group, Llp | 803 | 0.00% | $6.04K | New | 0.00% |
| StoneX Group Inc. | 695 | 0.00% | $5.23K | New | 0.00% |
| Vanguard Capital Management LLC | 649 | 0.00% | $4.88K | New | 0.00% |
| Osaic Holdings, Inc. | 100 | 0.00% | $760 | – | 0.00% |
| Tower Research Capital LLC (TRC) | 73 | 0.00% | $550 | – | 0.00% |
| SBI Securities Co., Ltd. | 35 | 0.00% | $263 | +25 | 0.00% |
| UBS Group AG | 0 | 0.00% | $0 | −4,992 | 0.00% |
| TD Waterhouse Canada Inc. | 0 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 0M | 0.5% | 10 / 3 | 2 / 0 | 0M | 0M |
| Q1 2026 | 11 | 0M | 0.1% | 3 / 4 | 0 / 4 | 0M | 0M |
| Q4 2025 | 13 | 0M | 0.1% | 3 / 4 | 3 / 4 | 0M | 0M |
| Q3 2025 | 14 | 0M | 0.1% | 3 / 5 | 1 / 4 | 0M | 0M |
| Q2 2025 | 15 | 0M | 0.0% | 2 / 0 | 5 / 0 | 0M | 0M |
| Q1 2025 | 14 | 0M | 0.1% | 0 / 6 | 1 / 1 | 0M | 0M |
| Q4 2024 | 15 | 0M | 0.1% | 2 / 3 | 3 / 2 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.1% | 4 / 3 | 3 / 1 | 0M | 0M |
| Q2 2024 | 13 | 0M | 0.1% | 3 / 4 | 3 / 3 | 0M | 0M |
| Q1 2024 | 13 | 0M | 0.1% | 4 / 3 | 3 / 4 | 0M | 0M |
| Q4 2023 | 13 | 0M | 0.1% | 3 / 2 | 3 / 4 | 0M | 0M |
| Q3 2023 | 14 | 0M | 0.1% | 4 / 3 | 5 / 3 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Francisco Silva | VP of Research and Development, Director | 183,520 | 0.72% | Oct 20, 2025 |
| Lance Alstodt | President, CEO, COB, Director, 10% owner | 187,497 | 0.74% | Oct 20, 2025 |
| Robert Eugene Kristal | Chief Financial Officer | 7,994 | 0.03% | Feb 19, 2025 |
| Esha Randhawa | Director | – | – | Jul 30, 2026 |
| Steven Collier Brown | Director | – | – | Jul 24, 2026 |
| Jatinder Dhaliwal | Director | – | – | Jun 18, 2026 |
| Mika Grasso | Director | – | – | Jun 18, 2026 |
| Katharyn Field | Director | – | – | Jun 17, 2026 |
| Nickolay V. Kukekov | Director | 0 | – | Feb 19, 2025 |
| Patrick F. Williams | Director | 0 | – | Feb 19, 2025 |
| David A. Rosa | Director | 0 | – | Feb 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Francisco Silva VP of Research and Development, Director | Oct 6, 2025 | Award | +11,719 | $1.60 | $18.75K | 171,384 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Oct 6, 2025 | Award | +15,625 | $1.60 | $25.00K | 187,497 |
| Dale Broadrick 10% owner | Oct 28, 2024 | Sale | −1,112 | $1.58 | $1.76K | 445,933 |
| Francisco Silva VP of Research and Development, Director | Apr 9, 2024 | Buy | +6,600 | $1.25 | $8.25K | 155,759 |
| Francisco Silva VP of Research and Development, Director | Apr 8, 2024 | Buy | +476 | $1.13 | $538 | 147,927 |
| Francisco Silva VP of Research and Development, Director | Apr 8, 2024 | Buy | +1,232 | $1.17 | $1.44K | 149,159 |
| Lance Alstodt President, CEO, COB, Director | Mar 18, 2024 | Tax withholding | −17,633 | $1.39 | $24.51K | 171,872 |
| Francisco Silva VP of Research and Development, Director | Mar 18, 2024 | Tax withholding | −17,193 | $1.39 | $23.90K | 147,451 |
| Dale Broadrick 10% owner | Feb 9, 2024 | Buy | +86,041 | $1.32 | $113.57K | 477,972 |
| Dale Broadrick 10% owner | Feb 8, 2024 | Buy | +73,959 | $1.25 | $92.45K | 391,931 |
| Dale Broadrick 10% owner | Feb 8, 2024 | Buy | +83,626 | $1.34 | $112.06K | 447,045 |
| Dale Broadrick 10% owner | Feb 7, 2024 | Buy | +36,374 | $1.38 | $50.20K | 363,419 |
| Dale Broadrick 10% owner | Dec 1, 2023 | Sale | −250 | $1.88 | $470 | 327,045 |
| Dale Broadrick 10% owner | Nov 27, 2023 | Sale | −278 | $1.89 | $525 | 327,295 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Sep 15, 2023 | Buy | +2,200 | $1.70 | $3.74K | 189,505 |
| Dale Broadrick 10% owner | Sep 15, 2023 | Buy | +10,000 | $1.66 | $16.60K | 327,573 |
| Dale Broadrick 10% owner | Sep 14, 2023 | Buy | +10,000 | $1.54 | $15.40K | 317,573 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Sep 13, 2023 | Buy | +800 | $1.53 | $1.22K | 188,105 |
| Dale Broadrick 10% owner | Sep 7, 2023 | Buy | +1,000 | $1.91 | $1.91K | 317,972 |
| Dale Broadrick 10% owner | Sep 7, 2023 | Buy | +1,000 | $1.81 | $1.81K | 307,573 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Sep 6, 2023 | Buy | +2,887 | $1.96 | $5.66K | 187,305 |
| Francisco Silva VP of Research and Development, Director, 10% owner | Aug 31, 2023 | Buy | +4,954 | $2.22 | $11.00K | 164,644 |
| Dale Broadrick 10% owner | Jul 28, 2023 | Buy | +500 | $2.89 | $1.45K | 306,573 |
| Dale Broadrick 10% owner | Jul 27, 2023 | Buy | +1,000 | $2.80 | $2.80K | 306,073 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Jul 25, 2023 | Buy | +4,200 | $2.44 | $10.25K | 184,418 |
| Francisco Silva VP of Research and Development, Director, 10% owner | Mar 31, 2023 | Buy | +747 | $3.56 | $2.66K | 159,690 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Mar 20, 2023 | Tax withholding | −6,729 | $2.92 | $19.65K | 180,218 |
| Francisco Silva VP of Research and Development, Director, 10% owner | Mar 20, 2023 | Tax withholding | −6,729 | $2.92 | $19.65K | 158,943 |
| Dale Broadrick 10% owner | Feb 22, 2023 | Buy | +5,000 | $2.84 | $14.20K | 304,073 |
| Dale Broadrick 10% owner | Feb 22, 2023 | Buy | +1,000 | $2.95 | $2.95K | 305,073 |
| Francisco Silva VP of Research and Development, Director, 10% owner | Feb 18, 2023 | Tax withholding | −374 | $2.99 | $1.12K | 165,672 |
| Lance Alstodt President, CEO, COB, Director, 10% owner | Feb 18, 2023 | Tax withholding | −374 | $2.99 | $1.12K | 186,947 |
| Lance Alstodt President, CEO, COB, Director | Feb 1, 2023 | Buy | +400 | $3.10 | $1.24K | 187,321 |
| Lance Alstodt President, CEO, COB, Director | Jan 27, 2023 | Buy | +200 | $3.01 | $602 | 186,921 |
| Lance Alstodt President, CEO, COB, Director | Jan 20, 2023 | Buy | +100 | $3.17 | $317 | 186,721 |
| Lance Alstodt President, CEO, COB, Director | Jan 20, 2023 | Buy | +100 | $3.10 | $310 | 186,621 |
| Lance Alstodt President, CEO, COB, Director | Jan 18, 2023 | Buy | +100 | $3.10 | $310 | 186,421 |
| Lance Alstodt President, CEO, COB, Director | Jan 18, 2023 | Buy | +200 | $3.13 | $626 | 186,321 |
| Lance Alstodt President, CEO, COB, Director | Jan 18, 2023 | Buy | +100 | $3.09 | $309 | 186,521 |
| Lance Alstodt President, CEO, COB, Director | Jan 9, 2023 | Buy | +100 | $3.08 | $308 | 186,121 |
| Lance Alstodt President, CEO, COB, Director | Dec 23, 2022 | Buy | +200 | $3.02 | $604 | 185,921 |
| Lance Alstodt President, CEO, COB, Director | Dec 23, 2022 | Buy | +100 | $2.99 | $299 | 186,021 |
| Lance Alstodt President, CEO, COB, Director | Dec 7, 2022 | Buy | +1,800 | $2.99 | $5.38K | 185,721 |
| Dale Broadrick 10% owner | Nov 30, 2022 | Buy | +100 | $2.78 | $278 | 298,973 |
| Dale Broadrick 10% owner | Nov 30, 2022 | Buy | +100 | $2.77 | $277 | 299,073 |
| Francisco Silva VP of Research and Development, Director | Nov 21, 2022 | Buy | +943 | $2.62 | $2.47K | 166,046 |
| Lance Alstodt President, CEO, COB, Director | Nov 18, 2022 | Buy | +1,000 | $2.88 | $2.88K | 183,921 |
| Francisco Silva VP of Research and Development, Director | Oct 12, 2022 | Buy | +725 | $3.39 | $2.46K | 165,103 |
| Francisco Silva VP of Research and Development, Director | Oct 11, 2022 | Buy | +806 | $3.69 | $2.97K | 164,378 |
| Dale Broadrick 10% owner | Sep 23, 2022 | Buy | +300 | $2.83 | $849 | 298,873 |
| Lance Alstodt President, CEO, COB, Director | Sep 22, 2022 | Buy | +100 | $2.85 | $285 | 182,921 |
| Lance Alstodt President, CEO, COB, Director | Sep 22, 2022 | Buy | +100 | $2.99 | $299 | 182,821 |
| Francisco Silva VP of Research and Development, Director | Aug 29, 2022 | Buy | +2,816 | $3.21 | $9.04K | 163,572 |
| Francisco Silva VP of Research and Development, Director | Aug 29, 2022 | Buy | +307 | $3.32 | $1.02K | 12,136 |
| Francisco Silva VP of Research and Development, Director | Aug 26, 2022 | Buy | +2,600 | $3.35 | $8.71K | 160,756 |
| Francisco Silva VP of Research and Development, Director | Aug 26, 2022 | Sale | −3,958 | $3.39 | $13.42K | 158,156 |
| Dale Broadrick 10% owner | Jul 13, 2022 | Buy | +200 | $3.00 | $600 | 298,573 |
| Dale Broadrick 10% owner | Jul 12, 2022 | Buy | +900 | $2.97 | $2.67K | 298,373 |
| Lance Alstodt President, CEO, COB, Director | Jul 12, 2022 | Buy | +700 | $2.95 | $2.07K | 182,721 |
| Dale Broadrick 10% owner | Jul 6, 2022 | Buy | +100 | $3.38 | $338 | 297,473 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioRestorative Therapies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,810 shares on Sep 4, 2026 over the last 90 days.
See a number that looks wrong?